ZTS has been the subject of a number of other reports. Zacks Investment Research raised shares of Zoetis from a hold rating to a buy rating and set a $71.00 price objective for the company in a research note on Thursday, October 12th. Cantor Fitzgerald reissued a buy rating and issued a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a hold rating to a sell rating in a research note on Friday, October 6th. Morgan Stanley lifted their price objective on shares of Zoetis from $61.00 to $70.00 and gave the stock an equal weight rating in a research note on Friday, November 3rd. Finally, The Goldman Sachs Group, Inc. reissued a neutral rating and issued a $62.00 price objective on shares of Zoetis in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company. Zoetis presently has an average rating of Buy and an average price target of $67.65.
Shares of Zoetis (NYSE ZTS) traded up $0.38 during trading hours on Friday, hitting $70.79. 2,337,803 shares of the company’s stock were exchanged, compared to its average volume of 2,806,257. Zoetis has a 1-year low of $48.55 and a 1-year high of $71.12. The stock has a market cap of $34,310.00, a PE ratio of 32.06, a P/E/G ratio of 2.04 and a beta of 1.02. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the company posted $0.52 EPS. The business’s revenue was up 8.5% on a year-over-year basis. equities research analysts forecast that Zoetis will post 2.37 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.59%. Zoetis’s dividend payout ratio is presently 22.11%.
Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. boosted its position in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Harfst & Associates Inc. boosted its position in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after buying an additional 260 shares during the period. Almanack Investment Partners LLC. purchased a new stake in Zoetis in the 2nd quarter valued at about $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after buying an additional 1,360 shares during the period. Finally, Peddock Capital Advisors LLC purchased a new stake in Zoetis in the 2nd quarter valued at about $140,000. 92.44% of the stock is owned by institutional investors.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.